Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of Petrelintide in Healthy and Overweight Subjects
NCT05096598Phase 1Completed
- Sponsor
- Zealand Pharma
- Start
- Oct 2021
- Primary completion
- Jan 2023
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing ZP8396 with Placebo (2 arms). Primary endpoint: Incidence of treatment emergent adverse events. Started Oct 2021; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05096598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05096598.